AstraZeneca revenues up as it delivers jab to 120 countries via Covax
Quarterly results from Anglo-Swedish producer of Covid vaccine show better-than-expected 15% rise
AstraZeneca has generated $275m (£197m) in revenues from its Covid vaccine in the first three months of the year and shipped 48m doses to 120 countries through the global vaccine-sharing initiative Covax.
Most of the vaccine sales ($224m) were in Europe – as the Anglo-Swedish drugmaker reported overall quarterly revenues up 15% to $7.3bn, better than analysts had expected. New medicines, such as the diabetes drug Farxiga, contributed more than half of revenues. The firm made a pre-tax profit of $1.6bn, up 72% year-on-year.
Continue reading...Coronavirus | The Guardian
Comments
Post a Comment